Lilly’s New $2.5 Billion Plant to Boost Obesity Drug Supply
- US drugmaker to invest $2.5 billion in factory near Frankfurt
- Plant marks biggest pharma industry investment in decades
This article is for subscribers only.
Eli Lilly & Co. kicked off construction of a plant to boost the production of its wildly popular weight-loss drugs, which have yet to gain a foothold in Europe.
The factory will open in 2027 and ship worldwide, the US drugmaker said at the groundbreaking ceremony near Frankfurt on Monday.